Inactive Instrument

All News Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Global markets live: Booking, Diageo, AT&T, Nvidia, UBS...	Feb. 23
EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"	Feb. 22	AN
AstraZeneca Completes Gracell Biotechnologies Acquisition	Feb. 22	MT
Stifel Downgrades Gracell Biotechnologies to Hold From Buy, Trims Price Target to $10.25 From $11	Feb. 22	MT
AstraZeneca completes acquisition of Gracell Biotechnologies	Feb. 22	CF
AstraZeneca Closes Purchase of Gracell Biotechnologies	Feb. 22	MT
Gracell Biotechnologies Acquisition Completed	Feb. 22	GL
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite Index	Feb. 21	CI
AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. from a group of shareholders.	Feb. 21	CI
Gracell Biotechnologies Announces Shareholders Approval of Merger Agreement	Feb. 21	AQ
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Biotechnology Index	Feb. 20	CI
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement	Feb. 20	GL
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement	Feb. 20	AQ
Gracell Biotechnologies Cleared for Early-Stage Trial of Prospective Multiple Myeloma Treatment	Jan. 29	MT
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma	Jan. 29	GL
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma	Jan. 29	AQ
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T Gc012F as Early-Line Treatment of Multiple Myeloma	Jan. 29	CI
Gracell Biotechnologies : Investor Frequently Asked Questions, dated December 29, 2023 - Form 6-K	Jan. 02	PU
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL	Dec. 31	BU
AstraZeneca to Buy China’s Gracell For $1.2 Billion	Dec. 27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

All News

Filters